Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Domino effect: Ipsen follows Biovail in dumping Santhera's fipamezole

This article was originally published in Scrip

Executive Summary

Ipsen has returned the rights to Santhera Pharmaceuticals' Phase II investigational treatment for levodopa-induced dyskinesia in Parkinson's disease, forgoing the €13 million upfront payment it made when it signed the deal. But it was only a matter of time: just weeks after Ipsen acquired rights to fipamezole for territories outside the US and Japan back in September 2010, a significant factor in the strategic rationale for the deal evaporated with the discontinuation by Biovail of its own work on the product.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts